Clinical Evaluation of the Aptima® Combo 2® Assay Using the Panther® System in Female Urine Samples

TerminatedOBSERVATIONAL
Enrollment

1,766

Participants

Timeline

Start Date

June 30, 2016

Primary Completion Date

March 1, 2017

Study Completion Date

March 1, 2017

Conditions
Chlamydia TrachomatisGonorrhea
Trial Locations (18)

23456

Tidewater Clinical Research, Inc., Virginia Beach

27215

LabCorp, Burlington

33161

Segal Institute for Clinical Research, Miami

35294

The University of Alabama at Birmingham, Birmingham

37804

Geneuity, Maryville

43210

The Ohio State University, Columbus

44106

University Hospitals Case Medical Center, Cleveland

45267

University of Cincinnati, Cincinnati

46202

Eskenazi Hospital - Indiana University School of Medicine, Indianapolis

49009

Beyer Research, Kalamazoo

68114

Quality Clinical Research, Inc., Omaha

70471

Clinical Trials Management, LLC, Mandeville

75062

Brownstone Clinical Trials, Irving

77023

Planned Parenthood Gulf Coast, Inc., Houston

78229

Clinical Trials of Texas, Inc., San Antonio

97204

Multnomah County Health Department, STD Clinic, Portland

98104

University of Washington Center for AIDS & STD, Seattle

06511

Planned Parenthood of Southern New England, Inc, New Haven

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Hologic, Inc.

INDUSTRY

NCT02795975 - Clinical Evaluation of the Aptima® Combo 2® Assay Using the Panther® System in Female Urine Samples | Biotech Hunter | Biotech Hunter